EUVIMEDEUVIMED entdecken
Crossref

Glucagon-Like Peptide-1 Receptor Agonist potential in AUD treatment. Neurobiological Mechanisms and Clinical Evidence

Paulina Wądołowska, Patryk Pindlowski, Ewelina Komorowska, Jakub Szyszkowski, Zuzanna Zgrzywa, Brygida Tucka, Natalia Kriese, Izabela Zawadzka, Bartłomiej Kowalski, Jakub Jaworski

Medical Science · 30.03.2026 · 30 (169) · 1-7

DOI: 10.54905/disssi.v30i169.e49ms3791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Science, online erschienen am 30.03.2026. Verfasst von Paulina Wądołowska und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alcohol Use Disorder (AUD) constitutes a significant global health challenge, with standard pharmacological treatments constrained by limited long-term efficacy and poor patient adherence.Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), originally used in the management of diabetes, have recently been identified as potential treatment for AUD due to their influence on the gut-brain axis and mesolimbic reward circuit.This review synthesizes evidence from a systematic search of PubMed and Scopus (January 2010 to July 2025), with emphasis on contemporary GLP-1 RAs such as Semaglutide, Liraglutide, and Exenatide.Preclinical studies consistently show that GLP-1 RAs reduce alcohol intake, motivation, and relapse-like behaviors in animal models by modulating dopaminergic signalling in the structures of the reward system.Cohorts and early randomized clinical trials provide indications that GLP-1 RAs treatment results in a reduction in the prevalence of Heavy Drinking Days and craving, potentially induced by the cross-reward effect.Although the safety profile appears favorable, most of the evidence comes from retrospective data and pilot studies.In summary, GLP-1 RAs are a promising intervention for AUD.However, there is still a requirement for large-scale randomized controlled trials with standardized abstinence endpoints to establish their efficacy and future clinical utility.

Zitieren

APA

Wądołowska, P., Pindlowski, P., Komorowska, E., Szyszkowski, J., Zgrzywa, Z., Tucka, B., Kriese, N., Zawadzka, I., Kowalski, B., & Jaworski, J. (2026). Glucagon-Like Peptide-1 Receptor Agonist potential in AUD treatment. Neurobiological Mechanisms and Clinical Evidence. Medical Science, 30(169), 1-7. https://doi.org/10.54905/disssi.v30i169.e49ms3791

Vancouver

Wądołowska P, Pindlowski P, Komorowska E, Szyszkowski J, Zgrzywa Z, Tucka B, et al. Glucagon-Like Peptide-1 Receptor Agonist potential in AUD treatment. Neurobiological Mechanisms and Clinical Evidence. Medical Science. 2026;30(169):1-7. doi:10.54905/disssi.v30i169.e49ms3791

BibTeX
@article{Wdoowska2026,
  author = {Wądołowska, Paulina and Pindlowski, Patryk and Komorowska, Ewelina and Szyszkowski, Jakub and Zgrzywa, Zuzanna and Tucka, Brygida and Kriese, Natalia and Zawadzka, Izabela and Kowalski, Bartłomiej and Jaworski, Jakub},
  title = {Glucagon-Like Peptide-1 Receptor Agonist potential in AUD treatment. Neurobiological Mechanisms and Clinical Evidence},
  journal = {Medical Science},
  year = {2026},
  volume = {30},
  number = {169},
  pages = {1--7},
  doi = {10.54905/disssi.v30i169.e49ms3791}
}
Kostenlos starten →